Correction to: Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy (Advanced Materials, (2022), 34, 35, 10.1002/adma.202204765)

Adv. Mater. 2022, 34, 2204765 DOI: 10.1002/adma.202204765 The H&E image of the PAS^siNCEV L+ group in Figure 5f and the immunofluorescent images of HMGB1 in the PBS and PAS^siNCEV L+ groups in Figure S19c (Supporting Information) were used in error. The authors identified the mistake, and the corrected Figures 5f and S19c (Supporting Information) are as follows: Figure 5f. Representative images for hematoxylin and eosin (H&E) staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and Ki67 assay of the excised tumors. Scale bar: 100 µm. Figure S19c. Immunofluorescence imaging and quantitative analysis of CRT exposure and HMGB1 release in the primary tumor tissues of CT26-Luc tumor-bearing mice. Blue, cell nuclei. Red, CRT (the upper rows), and HMGB1 (the lower rows). Scale bar, 100 µm. Statistical significance was performed by one-way ANOVA with a Tukey post hoc test. ^*p < 0.05, ^**p < 0.01, ^****p < 0.0001. We apologize for the error. The correction does not affect the conclusion drawn from the paper.